Delisting risk
Mereo BioPharma Group (ADR) (MREO)
Advances acquired rare-disease drug candidates through clinical development and partnerships.
$0.2651
Pre-market−0.00 (−0.75%)
At close$0.2671(−3.47%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions67 holders · as of Mar 31, 2026 | 47.20% | 75.38M ADS | |
| Insiders5 holders · as of Sep 16, 2024 | 0.78% | 1.25M ADS | |
| Strategic holders1 holder · as of Feb 11, 2022 | 1.18% | 1.88M ADS | |
| Otherremainder | 50.84% | 81.18M ADS |
159.69M ADS (1 ADS = 5 ordinary shares) as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
67 holders · 75.38M shares · 13 new positions · 28 increased · 18 reduced · 24 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Rubric Capital Management LP | 15.31M | 9.59% | 0 | May 15, 2026 |
| Ecor1 Capital, LLC | 13.37M | 8.37% | +5.51M | May 15, 2026 |
| 683 Capital Management, LLC | 12.00M | 7.51% | −3.03M | May 15, 2026 |
| Bank of America Corp /DE/ | 8.20M | 5.13% | +8.17M | May 18, 2026 |
| Defilade Capital Management, L.P. | 7.56M | 4.73% | +7.56Mnew | Jun 12, 2026 |
| Newtyn Management, LLC | 7.08M | 4.43% | +6.85M | May 15, 2026 |
| Millennium Management LLC | 3.56M | 2.23% | +3.48M | May 15, 2026 |
| Tejara Capital Ltd | 2.04M | 1.28% | −122.2K | May 12, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 8.40% | 66.84M | 13G | May 15, 2026 ↗ |
| 683 Capital Management, LLC | 8.18% | 65.08M | 13G | Jan 6, 2026 ↗ |
| Bank of America Corp /DE/ | 5.10% | 40.98M | 13G | May 14, 2026 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.